Highlights of the 2016 European Society of Cardiology Guidelines on Heart Failure
Highlights of the 2016 European Society of Cardiology Guidelines on Heart Failure
复制标题
DOI：
10.15420/ecr.2017:5:2
复制
发表时间：
2017-12-01
影响因子：
3
通讯作者：
Bayes-Genis, Antoni
中科院分区：
文献类型：
--
作者：
Bayes-Genis, Antoni
欧洲心脏病学会心力衰竭（HF）诊断和治疗指南于2016年更新。在本文中，重点介绍了基于新发现和实用建议所做的更新。2016年指南包括诊断不同类型心衰的定义和标准。此外，提出了一种新开发的算法，用于治疗特别是有射血分数降低的症状性心衰，包括使用血管紧张素转换酶抑制剂、β受体阻滞剂、矿皮质激素受体拮抗剂和血管紧张素受体奈普利素抑制剂sacubitril/缬沙坦。心衰诊断和治疗的某些方面需要进一步的证据，但这些指南将证明对这种情况下的决策是有用的。
The European Society of Cardiology guidelines for the diagnosis and treatment of heart failure (HF) was updated in 2016. In this article, highlights of the updates made based on new findings and practical recommendations are presented. The 2016 guidelines include definitions and criteria for diagnosing the different types of HF. In addition, a newly developed algorithm is proposed for treating particularly symptomatic HF with reduced ejection fraction, including the use of the angiotensin-converting enzyme inhibitors, beta-blockers, mineralocorticoid receptor antagonists and the angiotensin receptor neprilysin inhibitor sacubitril/valsartan. Further evidence is required for some aspects of the diagnosis and treatment of HF, but these guidelines will prove useful for decision making in this setting.